|
GB9702088D0
(en)
|
1997-01-31 |
1997-03-19 |
Pharmacia & Upjohn Spa |
Matrix metalloproteinase inhibitors
|
|
HUP0000852A2
(hu)
*
|
1997-02-03 |
2001-05-28 |
Pfizer Products Inc. |
Aril-szulfonil-amino-hidroxámsav-származékok, valamint e vegyületeket tartalmazó gyógyászati készítmények
|
|
CN1265647A
(zh)
|
1997-07-31 |
2000-09-06 |
普罗克特和甘保尔公司 |
无环金属蛋白酶抑制剂
|
|
WO2000037433A1
(en)
*
|
1998-12-18 |
2000-06-29 |
Abbott Laboratories |
Inhibitors of matrix metalloproteinases
|
|
US6326516B1
(en)
|
1999-01-27 |
2001-12-04 |
American Cyanamid Company |
Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
|
|
US6225311B1
(en)
|
1999-01-27 |
2001-05-01 |
American Cyanamid Company |
Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
|
|
US6277885B1
(en)
|
1999-01-27 |
2001-08-21 |
American Cyanamid Company |
Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
|
|
US6313123B1
(en)
|
1999-01-27 |
2001-11-06 |
American Cyanamid Company |
Acetylenic sulfonamide thiol tace inhibitors
|
|
BR0007784A
(pt)
|
1999-01-27 |
2002-02-05 |
American Cyanamid Co |
Composto, método para inibir mudanças patológicas mediadas pela enzima que converte o tnf-alfa (tace) em um mamìfero, composição farmacêutica, e, processo para preparar um composto
|
|
US6753337B2
(en)
*
|
1999-01-27 |
2004-06-22 |
Wyeth Holdings Corporation |
Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
|
|
US6762178B2
(en)
|
1999-01-27 |
2004-07-13 |
Wyeth Holdings Corporation |
Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
|
|
US6200996B1
(en)
|
1999-01-27 |
2001-03-13 |
American Cyanamid Company |
Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
|
|
US6946473B2
(en)
*
|
1999-01-27 |
2005-09-20 |
Wyeth Holdings Corporation |
Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
|
|
US6340691B1
(en)
|
1999-01-27 |
2002-01-22 |
American Cyanamid Company |
Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
|
|
SK12462001A3
(sk)
|
1999-03-03 |
2002-04-04 |
The Procter & Gamble Company |
Inhibítory metaloproteáz
|
|
KR20010102486A
(ko)
|
1999-03-03 |
2001-11-15 |
데이비드 엠 모이어 |
알케닐- 및 알키닐-함유 메탈로프로테아제 저해제
|
|
SE0100902D0
(sv)
*
|
2001-03-15 |
2001-03-15 |
Astrazeneca Ab |
Compounds
|
|
SE0100903D0
(sv)
*
|
2001-03-15 |
2001-03-15 |
Astrazeneca Ab |
Compounds
|
|
JP2005507937A
(ja)
*
|
2001-11-01 |
2005-03-24 |
ワイス・ホールディングズ・コーポレイション |
マトリックスメタロプロテイナーゼおよびｔａｃｅ阻害剤としてのアレンアリールスルホンアミドヒドロキサム酸
|
|
SE0103710D0
(sv)
*
|
2001-11-07 |
2001-11-07 |
Astrazeneca Ab |
Compounds
|
|
JP4002927B2
(ja)
*
|
2002-05-29 |
2007-11-07 |
メルク エンド カムパニー インコーポレーテッド |
炭疸病治療および致死因子阻害に有用な化合物
|
|
SE0202539D0
(sv)
|
2002-08-27 |
2002-08-27 |
Astrazeneca Ab |
Compounds
|
|
GB0221246D0
(en)
*
|
2002-09-13 |
2002-10-23 |
Astrazeneca Ab |
Compounds
|
|
US7199155B2
(en)
*
|
2002-12-23 |
2007-04-03 |
Wyeth Holdings Corporation |
Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
|
|
WO2004060346A2
(en)
|
2002-12-30 |
2004-07-22 |
Angiotech International Ag |
Drug delivery from rapid gelling polymer composition
|
|
JP2006517960A
(ja)
*
|
2003-02-18 |
2006-08-03 |
ファイザー インコーポレイテッド |
Ｃ型肝炎ウイルスの阻害剤、それを使用する組成物および治療法
|
|
EP1599449A2
(en)
*
|
2003-02-25 |
2005-11-30 |
TopoTarget UK Limited |
Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors
|
|
CA2566191A1
(en)
*
|
2004-05-11 |
2005-12-15 |
Merck & Co., Inc. |
Process for making n-sulfonated-amino acid derivatives
|
|
SE0401762D0
(sv)
*
|
2004-07-05 |
2004-07-05 |
Astrazeneca Ab |
Novel compounds
|
|
US7648992B2
(en)
|
2004-07-05 |
2010-01-19 |
Astrazeneca Ab |
Hydantoin derivatives for the treatment of obstructive airway diseases
|
|
ITFI20040174A1
(it)
*
|
2004-08-03 |
2004-11-03 |
Protera S R L |
Derivati arilsolfonammidici dell'acido idrossammico ad azione inibitoria di metalloproteinasi
|
|
US20100003276A1
(en)
*
|
2004-12-07 |
2010-01-07 |
Hermes Jeffery D |
Methods for treating anthrax and inhibiting lethal factor
|
|
SE0403086D0
(sv)
*
|
2004-12-17 |
2004-12-17 |
Astrazeneca Ab |
Compounds
|
|
SE0403085D0
(sv)
*
|
2004-12-17 |
2004-12-17 |
Astrazeneca Ab |
Novel componds
|
|
TW200831488A
(en)
*
|
2006-11-29 |
2008-08-01 |
Astrazeneca Ab |
Novel compounds
|
|
WO2019102488A1
(en)
|
2017-11-27 |
2019-05-31 |
Council Of Scientific & Industrial Research |
Indole (sulfomyl) n-hydroxy benzamide derivatives as selective hdac inhibitors
|
|
WO2026015506A1
(en)
*
|
2024-07-11 |
2026-01-15 |
Purdue Research Foundation |
Dual inhibitors for hdac3 and hiv-1 pr
|